Latest News and Press Releases
Want to stay updated on the latest news?
Featured Releases
-
KEY LARGO, Fla., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Remedy's Nutrition®, a trusted natural supplement company since 1972 and a leader in premium herbal formulations, today announced the release of...
Read More -
VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on...
Read More
-
加利福尼亚州圣迭戈, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Sapu Nano 公司今日公布新的生物标志物数据,这些数据确定了一种分子特征,可以预测患者对Sapu003的敏感性。Sapu003是该公司开发的静脉注射型依维莫司Deciparticle™制剂。 这些数据将在 12 月 9 日至 12 月 12 日召开的圣安东尼奥乳腺癌研讨会 (SABCS)...
-
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August...
-
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC
-
New York, USA, Dec. 06, 2025 (GLOBE NEWSWIRE) -- GeekStake today released a macro-level market update examining risk indicators across major blockchain networks as global economic uncertainty...
-
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech...
-
Washington, D.C., Dec. 06, 2025 (GLOBE NEWSWIRE) -- A former CIA counter-terrorism officer is raising new alarms in his recent presentation about the speed and scale of China’s AI-powered military...
-
KEY LARGO, Fla., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Remedy's Nutrition®, a trusted natural supplement company since 1972 and a leader in premium herbal formulations, today announced the release of...
-
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted...
-
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show...
-
VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on...